Company & Sponsor Intelligence
Bayer
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials3
Recruiting0
Completed2
Countries2
Therapeutic footprint
alzheimersmultiple_sclerosisparkinsons
Indexed studies
NCT00761436Pilot Study of Safety and Efficacy of Spheramine
parkinsons · United StatesPHASE2
parkinsons · United StatesPHASE2
NCT01009359Evaluation of the Neuroinflammation Pattern of BAY85-8102 F-18, DPA-714 in Probable Alzheimers Disease Patients Versus Healthy Volunteers and Radiation Dosimetry of F 18, DPA-714 in Healthy Volunteers
alzheimers · FinlandPHASE1
alzheimers · FinlandPHASE1
NCT03408093Study of Betaferon Adherence in Patients With Multiple Sclerosis Treated With Interferon Beta-1b
multiple_sclerosis · COMPLETED
multiple_sclerosis · COMPLETED
Intelligence layer updated: 2026-10-29 06:17:44.639239+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →